Oeyen et al., 2019 - Google Patents
Bladder cancer diagnosis and follow-up: the current status and possible role of extracellular vesiclesOeyen et al., 2019
View HTML- Document ID
- 12091973145419807166
- Author
- Oeyen E
- Hoekx L
- De Wachter S
- Baldewijns M
- Ameye F
- Mertens I
- Publication year
- Publication venue
- International journal of molecular sciences
External Links
Snippet
Diagnostic methods currently used for bladder cancer are cystoscopy and urine cytology. Cystoscopy is an invasive tool and has low sensitivity for carcinoma in situ. Urine cytology is non-invasive, is a low-cost method, and has a high specificity but low sensitivity for low …
- 206010005003 Bladder cancer 0 title abstract description 161
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oeyen et al. | Bladder cancer diagnosis and follow-up: the current status and possible role of extracellular vesicles | |
| Oliveira et al. | Urinary biomarkers in bladder cancer: where do we stand and potential role of extracellular vesicles | |
| Lousada-Fernandez et al. | Liquid biopsy in oral cancer | |
| Logozzi et al. | Exosomes: a source for new and old biomarkers in cancer | |
| Perez et al. | A pilot study on the potential of RNA-associated to urinary vesicles as a suitable non-invasive source for diagnostic purposes in bladder cancer | |
| Zhang et al. | Combined elevation of microRNA-196a and microRNA-196b in sera predicts unfavorable prognosis in patients with osteosarcomas | |
| Marcuello et al. | Analysis of A 6-Mirna signature in serum from colorectal cancer screening participants as non-invasive biomarkers for advanced adenoma and colorectal cancer detection | |
| Choi et al. | CD5L as an extracellular vesicle-derived biomarker for liquid biopsy of lung cancer | |
| Ohyashiki et al. | Downregulation of plasma miR-215 in chronic myeloid leukemia patients with successful discontinuation of imatinib | |
| Yu et al. | Circulating microRNA biomarkers for lung cancer detection in East Asian populations | |
| Georgantzoglou et al. | Extracellular vesicles as biomarkers carriers in bladder cancer: diagnosis, surveillance, and treatment | |
| Huang et al. | Expression and diagnostic value of HE4 in pancreatic adenocarcinoma | |
| Ranković et al. | Epithelial-mesenchymal transition-related microRNAs and their target genes in colorectal cancerogenesis | |
| Liao et al. | High expression of LAMP3 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma | |
| Fontana et al. | Protein cargo of salivary small extracellular vesicles as potential functional signature of oral squamous cell carcinoma | |
| Lourenço et al. | Urinary extracellular vesicles as potential biomarkers for urologic cancers: An overview of current methods and advances | |
| Charpentier et al. | Noninvasive urine-based tests to diagnose or detect recurrence of bladder cancer | |
| O’Farrell et al. | Plasma extracellular vesicle miRNAs can identify lung cancer, current smoking status, and stable COPD | |
| Güllü Amuran et al. | New insights in bladder cancer diagnosis: urinary miRNAs and proteins | |
| Park et al. | MicroRNA profile for diagnostic and prognostic biomarkers in thyroid cancer | |
| Paolino et al. | The fatty acid and protein profiles of circulating CD81-positive small extracellular vesicles are associated with disease stage in melanoma patients | |
| Cho et al. | Screening plasma exosomal RNAs as diagnostic markers for cervical cancer: an analysis of patients who underwent primary chemoradiotherapy | |
| Nicoletti et al. | Diagnostic and prognostic role of extracellular vesicles in pancreatic cancer: current evidence and future perspectives | |
| Jeong et al. | GCC2 as a new early diagnostic biomarker for non-small cell lung cancer | |
| Wickenhauser et al. | Tumor microenvironment, HLA class I and APM expression in HPV-negative oral squamous cell carcinoma |